Nasdaq:IBRX
ImmunityBio, Inc.
A clinical-stage biotech firm advancing immune checkpoint inhibitor therapies for oncology with significant cash flow burn but promising pipeline potential.
Key Metrics
Investment Thesis
Bull Case
Investors might consider IBRX for exposure to a transformative oncology pipeline that could redefine cancer treatment standards upon successful clinical validation. The substantial marketable securities position of $154.5M provides a runway to support expensive R&D programs and potential commercialization milestones. Early-stage biotech stocks often offer asymmetric upside if the company secures key partnerships or regulatory approval for its novel immune checkpoint inhibitors.
Bear Case
The stock carries extreme downside risk given the negative shareholders' equity of $-499.6M and a retained earnings deficit exceeding $3.7B which indicates prolonged financial distress. High interest expenses of $60.9M combined with operating losses suggest the company may struggle to survive without additional dilutive financing rounds or strategic sales. The lack of commercial revenue and reliance on future clinical outcomes makes the valuation highly speculative and vulnerable to market corrections.
About ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) is a clinical-stage biotechnology company focused on developing novel immune checkpoint inhibitor therapies for oncology markets. The company leverages its proprietary technology to create next-generation cancer treatments that aim to overcome resistance in traditional immunotherapies. Key revenue drivers currently stem from research and development activities with minimal commercial product sales as of the latest reporting period.
Analysis
Management Discussion
Recent financial performance highlights a challenging period with net profit remaining negative at $-351.5M, reflecting high operational costs and significant non-operating losses of $95.6M. While revenue surged to $113.3M in 2025 compared to negligible figures in prior years, this growth is insufficient to offset the massive cash flow from operations burn of $-304.9M. The company's liquidity position remains critical with ending cash at $89.4M against current liabilities of $61.8M, requiring continued access to capital markets.
Industry Overview
The oncology sector is characterized by intense competition among major pharmaceutical firms and biotech startups racing to develop novel immunotherapies. Regulatory pathways for immune checkpoint inhibitors are well-established but crowded, requiring significant capital investment to achieve market differentiation and approval. Industry dynamics favor companies with proprietary targets that can overcome resistance in existing treatments while managing high failure rates in late-stage trials.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $240.0K | $622.0K | $14.7M | $113.3M |
| Cost of Revenue | $0 | $0 | $0 | $753.0K |
| Gross Profit | $240.0K | $622.0K | $14.7M | $112.5M |
| Operating Expenses | $351.5M | $362.9M | $358.9M | $368.6M |
| Operating Income | $-351.3M | $-362.2M | $-344.2M | $-256.0M |
| R&D | $248.1M | $232.4M | $190.1M | — |
| G&A | $102.7M | $129.6M | $168.8M | — |
| Stock-Based Comp | $40.2M | $49.2M | $34.4M | $36.8M |
| D&A | $18.3M | $18.5M | $17.6M | $15.5M |
| Depreciation | $16.3M | $16.5M | $15.5M | $13.4M |
| Amortization | — | $2.0M | $2.0M | — |
| Other OpEx | $681.0K | $886.0K | $0 | — |
| Non-Operating Income | $-66.0M | $-221.6M | $-69.5M | $-95.6M |
| Interest Expense | $63.5M | $129.2M | $114.7M | $60.9M |
| Pre-Tax Income | $-417.3M | $-583.9M | $-413.6M | $-351.6M |
| Income Tax | $34.0K | $-40.0K | $0 | $-135.0K |
| Continuing Ops | $-417.3M | $-583.9M | $-413.6M | $-351.5M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-417.3M | $-583.9M | $-413.6M | $-351.5M |
| Minority Interest | $-753.0K | $-656.0K | $-81.0K | $-74.0K |
| Net to Common | $-416.6M | $-583.2M | $-413.6M | $-351.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $140.6M | $294.1M | $184.6M | $314.9M |
| Cash & Equivalents | $104.6M | $265.5M | $143.4M | $88.3M |
| Marketable Securities | $2.5M | $1.0M | $6.4M | $154.5M |
| Accounts Receivable | — | — | $2.4M | $42.6M |
| Inventory | — | — | $8.3M | $910.0K |
| Prepaid Expenses | $31.5M | $25.6M | $23.9M | $28.5M |
| Other Current Assets | $1.9M | $2.0M | $293.0K | $46.0K |
| Long-Term Assets | $221.8M | $210.4M | $198.3M | $187.0M |
| PP&E (Net) | $143.7M | $146.1M | $137.1M | $114.3M |
| Intangibles | $20.0M | $17.1M | — | — |
| Goodwill | — | — | $910.0K | $910.0K |
| Operating Leases | $45.8M | $36.5M | $33.4M | $33.0M |
| LT Securities | $840.0K | $891.0K | $0 | — |
| Other LT Assets | $11.5M | $9.8M | $27.0M | $38.8M |
| Total Assets | $362.4M | $504.5M | $382.9M | $501.9M |
| Current Liabilities | $500.9M | $58.3M | $54.9M | $61.8M |
| Accounts Payable | $21.0M | — | — | — |
| Current Leases | $2.6M | $5.2M | $7.5M | $7.5M |
| Other Current Liab | $435.4M | $10.3M | $6.9M | $7.4M |
| Long-Term Liabilities | $311.3M | $1.03B | $816.1M | $939.7M |
| LT Operating Leases | $48.0M | $39.9M | $34.8M | $33.4M |
| Other LT Liab | $263.4M | $992.2M | $781.3M | $906.3M |
| Total Liabilities | $812.2M | $1.09B | $871.1M | $1.00B |
| Shareholders' Equity | $-449.8M | $-585.9M | $-488.1M | $-499.6M |
| Retained Earnings | $-2.38B | $-2.96B | $-3.38B | $-3.73B |
| AOCI | $183.0K | $10.0K | $1.2M | $29.0M |
| Total L&E | $362.4M | $504.5M | $382.9M | $501.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-417.3M | $-583.9M | $-413.6M | $-351.5M |
| Non-Cash Adjustments | $57.5M | $227.7M | $22.5M | $-2.2M |
| Working Capital Changes | $22.3M | $-10.6M | $-111.0K | $48.7M |
| Cash from Operations | $-337.5M | $-366.8M | $-391.2M | $-304.9M |
| Capital Expenditures | $78.2M | $30.6M | $6.9M | $3.8M |
| Cash from Investing | $27.3M | $-30.5M | $-12.2M | $-149.8M |
| Cash from Financing | $233.6M | $558.3M | $281.6M | $400.2M |
| FX Effect | $284.0K | $-292.0K | $-23.0K | $15.0K |
| Net Change in Cash | $-76.3M | $160.8M | $-121.9M | $-54.5M |
| Beginning Cash | $181.3M | $105.0M | $265.8M | $143.9M |
| Ending Cash | $105.0M | $265.8M | $143.9M | $89.4M |
Frequently Asked Questions
How does ImmunityBio, Inc. make money?
The company operates primarily through its proprietary therapeutic discovery platform, focusing on developing immune checkpoint inhibitors that target specific cancer pathways. Revenue is currently driven by strategic collaborations and pre-revenue product candidates in the oncology space, while operating expenses are heavily weighted toward R&D and share-based compensation totaling $36.8M.
What are the main risks for IBRX?
Significant financial risk is present due to substantial net losses of $351.5M and high interest expenses of $60.9M that could constrain liquidity if financing conditions deteriorate. The company faces severe regulatory uncertainty as it lacks approved products and relies on future clinical trial success in a highly competitive oncology market. Operational risks include the potential for failed Phase 2 or 3 trials which would invalidate current valuation assumptions and accelerate cash burn. Additionally, the massive long-term liabilities of $939.7M suggest potential off-balance-sheet obligations or complex debt structures that could impact solvency.
What is IBRX's competitive advantage?
ImmunityBio possesses a differentiated portfolio of proprietary immune checkpoint targets not yet explored by major competitors, providing a unique path to market approval. The company maintains a strong balance sheet relative to its peers in early-stage development with $89.4M in cash and equivalents alongside $154.5M in marketable securities. Its focus on overcoming resistance mechanisms in existing immunotherapies addresses a critical unmet need in the cancer treatment landscape.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.